Mangalam Drugs & Organics Limited (BOM:532637)

Mangalam Drugs & Organics Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	7.51	25.89	11.87	26.88	19.55
Cash & Short-Term Investments	7.51	25.89	11.87	26.88	19.55
Cash Growth	-70.98%	118.07%	-55.84%	37.54%	230.26%
Accounts Receivable	402.97	390.73	279.44	465.33	464.9
Receivables	434.66	401.67	291.1	465.78	465.26
Inventory	1,028	1,388	1,236	1,375	1,171
Prepaid Expenses	-	15.61	16.1	18.74	20.54
Other Current Assets	87.21	158.65	204.53	179.77	173.92
Total Current Assets	1,557	1,990	1,760	2,066	1,850
Property, Plant & Equipment	1,260	1,336	1,269	1,336	1,268
Long-Term Investments	0.04	-	-	0.04	0.04
Other Intangible Assets	329.8	60.2	121.54	182.99	138.76
Long-Term Deferred Charges	-	258.11	163.64	-	-
Other Long-Term Assets	2.85	20.12	22.94	11.89	27.18
Total Assets	3,150	3,664	3,337	3,596	3,284

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	759.14	911.49	661.62	970.73	545.47
Accrued Expenses	13.65	47.93	40.57	40.01	38.29
Short-Term Debt	945.58	719.37	745.96	495.67	470.96
Current Portion of Long-Term Debt	72.7	70.65	84.99	62.59	66.15
Current Portion of Leases	23.61	54.79	54.09	72.15	38.77
Current Income Taxes Payable	-	9.18	-	3.76	22.7
Current Unearned Revenue	-	29	46.61	-	-
Other Current Liabilities	151.13	73.58	6.78	8.67	118.81
Total Current Liabilities	1,966	1,916	1,641	1,654	1,301
Long-Term Debt	74.98	92.33	133.54	187.66	251.03
Long-Term Leases	10.66	25.16	51.34	67.39	52.14
Pension & Post-Retirement Benefits	-	13.54	19.28	22.93	39.39
Long-Term Deferred Tax Liabilities	52.01	98.15	120.86	145.16	134.95
Other Long-Term Liabilities	15.65	29.25	13.45	0	0.01
Total Liabilities	2,119	2,174	1,979	2,077	1,779

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	158.28	158.28	158.28	158.28	158.28
Additional Paid-In Capital	-	223.75	223.75	223.75	223.75
Retained Earnings	-	1,037	975.89	1,141	1,128
Comprehensive Income & Other	872.31	70.81	-	-3.02	-4.27
Shareholders' Equity	1,031	1,490	1,358	1,520	1,506
Total Liabilities & Equity	3,150	3,664	3,337	3,596	3,284

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	1,128	962.3	1,070	885.47	879.04
Net Cash (Debt)	-1,120	-936.41	-1,058	-858.58	-859.5
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-70.76	-59.16	-66.85	-54.24	-54.30
Filing Date Shares Outstanding	15.83	15.83	15.83	15.83	15.83
Total Common Shares Outstanding	15.83	15.83	15.83	15.83	15.83
Working Capital	-408.69	73.84	119.39	412.27	549.19
Book Value Per Share	65.12	94.12	85.79	96.00	95.12
Tangible Book Value	700.79	1,430	1,236	1,337	1,367
Tangible Book Value Per Share	44.28	90.32	78.11	84.44	86.36
Land	-	86.62	11.29	5.44	5.44
Buildings	-	374.79	371.23	370.13	369.83
Machinery	-	1,836	1,661	1,604	1,592
Construction In Progress	-	-	-	64.04	1.8

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 27, 2026

Data Sources Report a data error